EPIRUS Biopharmaceuticals, Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Company’s lead product candidate, BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name, Infimab. The Company’s products include BOW015, which contains infliximab; BOW050, which contains adalimumab; BOW070, which contains tocilizumab; BOW080, which contains eculizumab; BOW090, which contains ustekinumab, and BOW100, which contains golimumab.
